Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

Neurology. 2010 Aug 31;75(9):831-3. doi: 10.1212/WNL.0b013e3181f07362.

Authors

T Lenhard¹, A Biller, W Mueller, I Metz, J Schönberger, B Wildemann

Affiliation

¹ Division of Molecular Neuroimmunology, Department of Neurology, University Hospital Heidelberg, INF 400, D-69120 Heidelberg, Germany.

PMID: 20805529
DOI: 10.1212/WNL.0b013e3181f07362

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Female
Humans
Immune Reconstitution Inflammatory Syndrome / diagnosis*
Immune Reconstitution Inflammatory Syndrome / etiology
Immune Reconstitution Inflammatory Syndrome / pathology
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Multiple Sclerosis, Relapsing-Remitting / pathology
Natalizumab
Substance Withdrawal Syndrome / diagnosis*
Substance Withdrawal Syndrome / etiology
Substance Withdrawal Syndrome / pathology

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Natalizumab